Lexicon Pharmaceuticals | LXRX - Ebitda


Lexicon Pharmaceuticals reported $-12.04M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Illumina USD 330M 80M Jun/2026
Insmed USD -148.3M 165.88M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 8.27B 1.08B Mar/2026
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD -30.2M 52.15M Mar/2026
MannKind USD 2.93M 5.98M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024